TargetGene Biotechnologies
Genome Editing for Living Organisms
Company Overview
Snapshot
Founded in October 2012 by Yoel Shiboleth and Dan Weinthal, TargetGene Biotechnologies operates with 1–10 employees. The company has raised $9.2M across two funding rounds from two investors. In December 2018, TargetGene Biotechnologies developed more precise gene editing technology.
Business overview
TargetGene Biotechnologies is an agile biotechnology company focused on developing efficient and highly specific DNA editing solutions for living organisms. The company's core technology is its patented and patent-pending TGEE (genome editing engine) platform, which utilizes RNA-guided gene targeting. TargetGene aims to apply the TGEE platform for human gene therapy, specifically targeting inherited diseases and cell-based immunotherapy, operating within the Health Tech & Life Sciences sector.
Strategic signal
In December 2019, an interview with CEO Yoel Shiboleth highlighted TargetGene's TGEE platform as a potential successor to CRISPR in gene editing. This signals a significant advancement in gene editing technology, positioning TargetGene as an innovator with a proprietary platform that could offer enhanced precision and efficiency, attracting investor interest in the competitive biotechnology landscape.
Company Intelligence Q&A
- What is TargetGene Biotechnologies' primary focus?
- TargetGene Biotechnologies is focused on creating efficient and highly specific DNA editing solutions for living organisms, particularly for human gene therapy targeting inherited diseases and cell-based immunotherapy.
- When was TargetGene Biotechnologies founded and by whom?
- TargetGene Biotechnologies was founded in October 2012 by Yoel Shiboleth and Dan Weinthal.
- What is the TGEE platform?
- The TGEE (genome editing engine) platform is TargetGene Biotechnologies' patented and patent-pending technology that utilizes RNA-guided gene targeting for precise DNA editing.
- What was a key development for TargetGene Biotechnologies in December 2018?
- In December 2018, TargetGene Biotechnologies developed more precise gene editing technology.
- What strategic partnership did TargetGene Biotechnologies form in June 2016?
- In June 2016, TargetGene Biotechnologies inked gene editing technology licensing deals with Monsanto.